RDNT vs WST
RadNet, Inc. vs West Pharmaceutical Services — AI-powered side-by-side comparison
RDNT
RadNet, Inc.
52
Watch
VS
WST
West Pharmaceutical Services
74
Buy
| Metric | RDNT | WST |
|---|
| AI Score |
52
|
74
|
| Price |
$76.28
|
$351.74
|
| P/E Ratio |
-286.45×
|
44.65×
|
| ROE |
-1.7%
|
15.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
9.7%
|
36.8%
|
| Debt / Equity |
1.99×
|
0.10×
|
| Dividend Yield |
0.0%
|
0.3%
|
| RSI (14) |
78.1
|
58.0
|
| Beta |
1.384
|
1.138
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for RDNT versus WST.
WST leads by 22 points.
WST scores 74/100 (Buy) versus RDNT at 52/100 (Watch).
RDNT Committee View
33% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — price-to-book of 5.1x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 5.1x prices in significant intangible value — Value
- ROE of only -1.4% -- cheap may mean cheap for a reason — Value
- RSI at 78 is in overbought territory — Technical
WST Committee View
100% agreement
5 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical